With a nod from reviewers at the FDA, Toshiba America Medical Systems has begun preparations to launch its Nemio series of ultrasound imaging systems. The new product line, which cleared the FDA on March 15, is scheduled to debut on May 8 at the Leading
With a nod from reviewers at the FDA, Toshiba America Medical Systems has begun preparations to launch its Nemio series of ultrasound imaging systems. The new product line, which cleared the FDA on March 15, is scheduled to debut on May 8 at the Leading Edge in Diagnostic Ultrasound conference in Atlantic City, NJ.
Nemio will coexist with the PowerVision series that now makes up the company’s U.S. ultrasound offering. Toshiba officials say the two product lines address different market segments.
The Nemio series will include three high-performance digital systems, each selling for less than $100,000. The black-and-white Nemio 10 and the color Nemio 20 are designed for radiology applications. The Nemio 30 is a shared-services product, capable of supporting most applications, including vascular and cardiology. A high-end configuration may be equipped to include 3-D imaging, panoramic view, and stress echo.
“Nemio 30 has all of the advanced applications you would typically find on a premium product,” said Michael Kingcaid, senior director of Toshiba’s ultrasound business unit. “It’s really designed for imaging, cardiology, radiology, and outpatient centers.”
Staff at Toshiba America Medical Systems have been working on the products for more than a year, building on earlier work completed by engineers in Japan. The systems can support fetal, abdominal, intraoperative, pediatric, small organ, neonatal cephalic, and adult cephalic studies. Also possible are cardiac, transrectal, transvaginal, transesophageal, peripheral vascular, musculoskeletal, and laparoscopic exams.
All three versions of Nemio are mobile and work with a range of probes, including flat linear array, convex linear array, and sector array, with a frequency range from 2 MHz to 12 MHz. Options such as monitor size and postprocessing display capabilities help differentiate the three systems, according to Kingcaid.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.